InsiderTrades.com logo
Kiss of death from Joe Biden
From Porter & Company   |   Ad
I did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.
I have uncovered a bombshell that changes everything… and threatens everything.

MIRA Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $1,941,704.00
Insider Selling (Last 12 Months): $618,577.14

MIRA Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at MIRA Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MIRA Pharmaceuticals Share Price & Price History

Current Price: $2.71
Price Change: ▼ Price Decrease of -0.33 (-10.86%)
As of 07/26/2024 01:00 AM ET

This chart shows the closing price history over time for MIRA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
J.P. Morgan’s DIRE Warning
From Behind the Markets   |   Ad
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
Click here to see why Wall Street is in PANIC mode >>>

MIRA Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/21/2024Erez AminovCEOBuy8,700$0.94$8,178.00382,200View SEC Filing Icon  
12/11/2023Brian Patrick McnultyMajor ShareholderSell46,005$1.55$71,307.75660,000View SEC Filing Icon  
12/8/2023Brian Patrick McnultyMajor ShareholderSell19,053$1.61$30,675.33683,002View SEC Filing Icon  
12/6/2023Brian Patrick McnultyMajor ShareholderSell27,733$2.95$81,812.35709,196View SEC Filing Icon  
12/4/2023Brian Patrick McnultyMajor ShareholderSell61,331$3.98$244,097.38723,062View SEC Filing Icon  
11/29/2023Brian Patrick McnultyMajor ShareholderSell7,399$3.98$29,448.02756,149View SEC Filing Icon  
11/27/2023Brian Patrick McnultyMajor ShareholderSell6,425$4.00$25,700.00759,969View SEC Filing Icon  
11/20/2023Brian Patrick McnultyMajor ShareholderSell26,733$5.07$135,536.31765,681View SEC Filing Icon  
8/7/2023George CappyMajor ShareholderBuy119,048$7.00$833,336.002,859,318View SEC Filing Icon  
8/2/2023George CappyMajor ShareholderBuy157,170$7.00$1,100,190.002,740,270View SEC Filing Icon  
See Full Table
J.P. Morgan’s DIRE Warning
From Behind the Markets   |   Ad
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
Click here to see why Wall Street is in PANIC mode >>>

SEC Filings (Institutional Ownership Changes) for MIRA Pharmaceuticals (NASDAQ:MIRA)

35.16% of MIRA Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

MIRA Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/20/2024Virtu Financial LLC63,055$69K0.0%+330.2%0.427%Search for SEC Filing on Google Icon
5/2/2024Suncoast Equity Management40,000$44K0.0%N/A0.271%Search for SEC Filing on Google Icon
5/2/2024Cross Staff Investments Inc383,401$0.42M0.4%N/A2.594%Search for SEC Filing on Google Icon
4/10/2024Praetorian Wealth Management Inc.27,500$30K0.0%N/A0.186%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
MIRA Pharmaceuticals logo
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.
Read More on MIRA Pharmaceuticals

Today's Range

Now: $2.71
Low: $2.55
High: $3.30

50 Day Range

MA: $0.94
Low: $0.54
High: $5.01

52 Week Range

Now: $2.71
Low: $0.51
High: $7.98

Volume

4,817,287 shs

Average Volume

2,330,615 shs

Market Capitalization

$40.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of MIRA Pharmaceuticals?

MIRA Pharmaceuticals' top insider shareholders include:
  1. George Cappy (Major Shareholder)
  2. Brian Patrick Mcnulty (Major Shareholder)
  3. Erez Aminov (CEO)
Learn More about top insider investors at MIRA Pharmaceuticals.
Kiss of death from Joe Biden
From Porter & Company   |   Ad
I did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.
I have uncovered a bombshell that changes everything… and threatens everything.